ArticleBiomaterials2016
A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer.
Article in Biomaterials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 75 citations in OpenAlex.
- The Anti-proliferative Effect, Apoptotic Induction, and Cell Cycle Arrest of Tetra Halo Ruthenate Nanocomposites in Different Human Cancer Cell Lines.Cell biochemistry and biophysics · 2025Article
- Integrating single-cell and bulk RNA sequencing data unveils antigen presentation and process-related CAFS and establishes a predictive signature in prostate cancer.Journal of translational medicine · 2024Article
- Multifunctional nanostructures: Intelligent design to overcome biological barriers.Materials today. Bio · 2023Review
- Review
- Mesenchymal Stromal Cell-Based Targeted Therapy Pancreatic Cancer: Progress and Challenges.International journal of molecular sciences · 2023Review
- Construction of a prognostic 6-gene signature for breast cancer based on multi-omics and single-cell data.Frontiers in oncology · 2023Article
- Biomimetic cell-derived nanocarriers in cancer research.Journal of nanobiotechnology · 2022Review
- Prostate Cancer Tumor Stroma: Responsibility in Tumor Biology, Diagnosis and Treatment.Cancers · 2022Review
- MSCs as Tumor-Specific Vectors for the Delivery of Anticancer Agents-A Potential Therapeutic Strategy in Cancer Diseases: Perspectives for Quinazoline Derivatives.International journal of molecular sciences · 2022Review
- Protease-triggered bioresponsive drug delivery for the targeted theranostics of malignancy.Acta pharmaceutica Sinica. B · 2021Review
- Importance of the origin of mesenchymal (stem) stromal cells in cancer biology: "alliance" or "war" in intercellular signals.Cell & bioscience · 2021Review
- A cell-based drug delivery platform for treating central nervous system inflammation.Journal of molecular medicine (Berlin, Germany) · 2021Article
- Mesenchymal Stem Cells as a Cornerstone in a Galaxy of Intercellular Signals: Basis for a New Era of Medicine.International journal of molecular sciences · 2021Review
- Mesenchymal stem cells as a double-edged sword in tumor growth: focusing on MSC-derived cytokines.Cellular & molecular biology letters · 2021Review
- Nanoparticle-Based Therapies for Turning Cold Tumors Hot: How to Treat an Immunosuppressive Tumor Microenvironment.Frontiers in bioengineering and biotechnology · 2021Review
- Thapsigargin-From Traditional Medicine to Anticancer Drug.International journal of molecular sciences · 2020Review
- Genetically engineered mesenchymal stem cells: targeted delivery of immunomodulatory agents for tumor eradication.Cancer gene therapy · 2020Review
- Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer.Molecular cancer therapeutics · 2020Article
- Shattering barriers toward clinically meaningful MSC therapies.Science advances · 2020Review
- Stem cell therapy: old challenges and new solutions.Molecular biology reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 1 country.
Funding
Abstract
Despite considerable advances in prostate cancer research, there is a major need for a systemic delivery platform that efficiently targets anti-cancer drugs to sites of disseminated prostate cancer while minimizing host toxicity. In this proof-of-principle study, human mesenchymal stem cells (MSCs) were loaded with poly(lactic-co-glycolic acid) (PLGA) microparticles (MPs) that encapsulate the macromolecule G114, a thapsigargin-based prostate specific antigen (PSA)-activated prodrug. G114-particles (∼950 nm in size) were internalized by MSCs, followed by the release of G114 as an intact prodrug from loaded cells. Moreover, G114 released from G114 MP-loaded MSCs selectively induced death of the PSA-secreting PCa cell line, LNCaP. Finally, G114 MP-loaded MSCs inhibited tumor growth when used in proof-of-concept co-inoculation studies with CWR22 PCa xenografts, suggesting that cell-based delivery of G114 did not compromise the potency of this pro-drug in-vitro or in-vivo. This study demonstrates a potentially promising approach to assemble a cell-based drug delivery platform, which inhibits cancer growth in-vivo without the need of genetic engineering. We envision that upon achieving efficient homing of systemically infused MSCs to cancer sites, this MSC-based platform may be developed into an effective, systemic 'Trojan Horse' therapy for targeted delivery of therapeutic agents to sites of metastatic PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.